Cilengitide

Cilengitide is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrines, which are important in angiogenesis (forming new blood vessels). Hence, it is investigated for treating cancer by inhibiting angiogenesis.